Advertisement

Leptin: Linking obesity, the metabolic syndrome, and cardiovascular disease

  • Sanjeev B. Patel
  • Garry P. Reams
  • Robert M. Spear
  • Ronald H. Freeman
  • Daniel VillarrealEmail author
Article

Abstract

The incidence and prevalence of obesity and the metabolic syndrome have risen markedly in the past decade, representing a serious cardiovascular health hazard with significant morbidity and mortality. The etiology of the metabolic syndrome and its various pathogenic mechanisms are incompletely defined and under intense investigation. Contemporary research suggests that the adipocyte-derived hormone leptin may be an important factor linking obesity, the metabolic syndrome, and cardiovascular disorders. Although recent evidence indicates that under normal conditions leptin may be an important factor in regulating pressure and volume, during situations of chronic hyperleptinemia and leptin resistance, this hormone may function pathophysiologically for the development of hypertension and cardiac and renal diseases. Future research will determine if reduction of circulating leptin and/or blockade of its peripheral actions can confer cardiovascular and renal protection in hyperleptinemic patients with obesity and the metabolic syndrome.

Keywords

Nitric Oxide Metabolic Syndrome Sympathetic Nervous System Sodium Excretion Urinary Sodium Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References and Recommended Reading

  1. 1.
    Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006, 295:1549–1555.PubMedCrossRefGoogle Scholar
  2. 2.
    Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity associated cardiovascular and renal disease. Am J Sci 2002, 324:127–137.CrossRefGoogle Scholar
  3. 3.
    Grundy SM, Brewer HB Jr, Cleeman JI, et al.: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433–438.PubMedCrossRefGoogle Scholar
  4. 4.
    Unger RH: Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003, 14:398–403.PubMedCrossRefGoogle Scholar
  5. 5.
    Unger RH: Hyperleptinemia: protecting the heart from lipid overload. Hypertension 2005, 45:1031–1034.PubMedCrossRefGoogle Scholar
  6. 6.
    Franks PW, Brage S, Luan J, et al.: Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005, 13:1476–1484.PubMedGoogle Scholar
  7. 7.
    Patel S, Villarreal D, Mukherjee R, et al.: Renal and vascular actions of leptin: Emerging concepts in obesity and hypertension. Adipocytes 2007, 2:101–108.Google Scholar
  8. 8.
    Banks AS, Davis SM, Bates SH, et al.: Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000, 275:14563–14572.PubMedCrossRefGoogle Scholar
  9. 9.
    Munzberg H, Myers MG Jr: Molecular and anatomical determinants of central leptin resistance. Nature 2005, 8:566–570.Google Scholar
  10. 10.
    Hoggard N, Mercer JG, Rayner DV: Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridization. Biochem Biophys Res Commun 1997, 232:383–387.PubMedCrossRefGoogle Scholar
  11. 11.
    Haynes WG, Morgan DA, Walsh SA, et al.: Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270–278.PubMedCrossRefGoogle Scholar
  12. 12.
    Dunbar JC, Hu Y, Lu H: Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997, 40:2043.Google Scholar
  13. 13.
    Guha PK, Villarreal D, Reams GP, et al.: Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 2003, 10:211–218.PubMedCrossRefGoogle Scholar
  14. 14.
    Villarreal D, Reams GP, Freeman RH, et al.: Renal effects of leptin in normotensive, hypertensive and obese rats. Am J Physiol 1998, 275:R2056–R2060.PubMedGoogle Scholar
  15. 15.
    Jackson EK, Li P: Human leptin has natriuretic activity in the rat. Am J Physiol 1997, 272:F333–F338.PubMedGoogle Scholar
  16. 16.
    Lembo L, Vecchione C, Fratta L: Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000, 49:293–297.PubMedCrossRefGoogle Scholar
  17. 17.
    Vecchione C, Maffei A, Colella S, et al.: Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002, 51:168–173.PubMedCrossRefGoogle Scholar
  18. 18.
    Fruhbeck G: Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999, 48:903–908.PubMedCrossRefGoogle Scholar
  19. 19.
    Mitchell JL, Morgan DA, Correia ML, et al.: Does leptin stimulate nitric oxide to oppose the effects of sympathetic activation? Hypertension 2001, 38:1081–1086.PubMedCrossRefGoogle Scholar
  20. 20.
    Gardiner SM, Kemp PA, March JE, et al.: Regional hemodynamic effects of recombinant murine or human leptin in conscious rats. Br J Pharmacol 2000, 130:805–810.PubMedCrossRefGoogle Scholar
  21. 21.
    Quehenberger P, Exner M, Sunder-Plassmann R, et al.: Leptin induces endothelin-1 endothelial cells in vitro. Circ Res 2002, 90:711–718.PubMedCrossRefGoogle Scholar
  22. 22.
    Bouloumine A, Marumo T, Lofanton M, et al.: Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13:1231–1238.Google Scholar
  23. 23.
    Beltowski J: Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006, 24:789–801.PubMedCrossRefGoogle Scholar
  24. 24.
    Correia MI, Haynes WG, Rahmouni K: The concept of selective leptin resistance: Evidence from agouti yellow obese mice. Diabetes 2002, 51:439–442.PubMedCrossRefGoogle Scholar
  25. 25.
    Rahmouni K, Correia LG, Haynes WG, et al.: Obesity-associated hypertension, new insights into mechanisms. Hypertension 2005, 45:9–14.PubMedCrossRefGoogle Scholar
  26. 26.
    Tune JD, Consodine R: Effects of leptin on cardiovascular physiology. J Am Soc Hypertens 2007, 14:231–241.CrossRefGoogle Scholar
  27. 27.
    Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409–414.PubMedGoogle Scholar
  28. 28.
    Aizawa-Abe M, Ogawa Y, Masuzaki H, et al.: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000, 105:1243–1252.PubMedCrossRefGoogle Scholar
  29. 29.
    Agata J, Masuda A, Takada M, et al.: High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997, 10:1171–1174.PubMedCrossRefGoogle Scholar
  30. 30.
    Kazumi T, Kawaguchi A, Katoh J, et al.: Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. J Hypertens 1999, 17:1451–1455.PubMedCrossRefGoogle Scholar
  31. 31.
    Makris TK, Stavroulakis GA, Krespi PG, et al.: Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension. Am Heart J 1999, 138:922–925.PubMedCrossRefGoogle Scholar
  32. 32.
    Serradeil-Le G, Raufaste D, Brossard G, et al.: Characterization and localization of leptin receptors in the rat kidney. FEBS Lett 1997, 404:185–191.CrossRefGoogle Scholar
  33. 33.
    Bado A, Levasseur S, Attoub S: The stomach is a source of leptin. Nature 1998, 394:790–793.PubMedCrossRefGoogle Scholar
  34. 34.
    Villarreal D, Reams GP, Freeman RH: Effects of renal denervaton on the sodium excretory action of leptin in hypertensive rats. Kidney Int 2000, 58:989–994.PubMedCrossRefGoogle Scholar
  35. 35.
    Beltowski J, Wojcicka G: Human leptin administered intraperitoneally stimulates natriuresis and decreases renal medullary Na+, K+-ATPase activity in the rat-impaired effect in dietary-induced obesity. Med Sci Monit 2002, 8: BR221–BR229.PubMedGoogle Scholar
  36. 36.
    Villarreal D, Reams GP, Samar H, et al.: Effects of chronic nitric oxide inhibition on the renal excretory response to leptin. Obes Res 2004, 12:1006–1010.PubMedGoogle Scholar
  37. 37.
    Ortiz PA, Garvin JL: Role of nitric oxide in the regulation of nephron transport. Am J Physiol 2002, 282:F777–F784.Google Scholar
  38. 38.
    Villarreal D, Reams GP, Samar H: Leptin blockade attenuates sodium excretion in saline-loaded normotensive rats. Mol Cell Biochem 2006, 283:153–157.PubMedCrossRefGoogle Scholar
  39. 39.
    Dobrian AD, Schriver SD, Lynch T, et al.: Effect of salt on hypertension and oxidative stress in rat model on diet-induced obesity. Am J Physiol 2003, 285:F619–F628.Google Scholar
  40. 40.
    Konstantinides S, Schafer K, Koschnick S, et al.: Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001, 108:1533–1540.PubMedGoogle Scholar
  41. 41.
    Sierra-Honigmann MR, Nath AK, Murakami C.: Biological action of leptin as an angiogenic factor. Science 1998, 281:1683–1686.PubMedCrossRefGoogle Scholar
  42. 42.
    Umemoto Y, Tsuji K, Yang FC, et al.: Leptin stimulates the proliferation of murine myelocytic and primitive haematopoietic progenitor cells. Blood 1997, 90:3438–3443.PubMedGoogle Scholar
  43. 43.
    Paolisso G, Tangliamonte MR, Galderisi M, et al.: Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin resistant men. Hypertension 1999, 34:1047–1052.PubMedGoogle Scholar
  44. 44.
    Luo J, Zhang G, Chen M: Leptin and cardiovascular diseases. Drug News Perspect 2005, 18:427–431.PubMedCrossRefGoogle Scholar
  45. 45.
    Karmazyn M, Purdham DM, Rajapurohitam V: Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc Med 2007, 17:206–211.PubMedCrossRefGoogle Scholar
  46. 46.
    Rajapurohitam V, Gan XT, Kirshenbaum LA, et al.: The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003, 93:277–279.PubMedCrossRefGoogle Scholar
  47. 47.
    Barouch LA, Berkowitz DE, Harrison RW, et al.: Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003, 108:754–759.PubMedCrossRefGoogle Scholar
  48. 48.
    Tajmir P, Ceddia RB, Li RK: Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 2004, 145:1550–1555.PubMedCrossRefGoogle Scholar
  49. 49.
    Atkinson LL, Fischer MA, Lopaschuk GD: Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 2002, 277:29424–29430.PubMedCrossRefGoogle Scholar
  50. 50.
    Nickola M, Wold L, Colligan P, et al.: Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 2000, 36:501–505.PubMedGoogle Scholar
  51. 51.
    Wold LE, Relling DP, Duan J, et al.: Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of JAK/STAT pathway. Hypertension 2002, 39:69–74.PubMedCrossRefGoogle Scholar
  52. 52.
    Tritos NA, Manning WJ, Danias PG, et al.: Role of leptin in the development of cardiac hypertrophy in experimental animals and humans. Circulation 2004, 109:e67.PubMedCrossRefGoogle Scholar
  53. 53.
    Schulze PC, Kratzsch J, Linke A, et al.: Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003, 5:33–40.PubMedCrossRefGoogle Scholar
  54. 54.
    Sharma V, McNeill J: The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology. Curr Vasc Pharmacol, 2005, 3:169–180.PubMedCrossRefGoogle Scholar
  55. 55.
    Wallace M, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104:3052–3056.PubMedCrossRefGoogle Scholar
  56. 56.
    Couillard C, Lamarche B, Mauriège P, et al.: Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998, 21:782–786.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Sanjeev B. Patel
  • Garry P. Reams
  • Robert M. Spear
  • Ronald H. Freeman
  • Daniel Villarreal
    • 1
    Email author
  1. 1.Department of Medicine, Division of CardiologySUNY Upstate Medical UniversitySyracuseUSA

Personalised recommendations